Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting

• Published in: Molecular cancer therapeutics Vol. 14; no. 7; pp. 1661 - 1670
• Main Authors: Smith, Rosamund C., Cramer, Martin S., Mitchell, Pamela J., Capen, Andrew, Huber, Lysiane, Wang, Rong, Myers, Laura, Jones, Bryan E., Eastwood, Brian J., Ballard, Darryl, Hanson, Jeff, Credille, Kelly M., Wroblewski, Victor J., Lin, Boris K., Heuer, Josef G.
• Format: Journal Article
• Language: English
• Published: United States 01.07.2015
• Subjects: Animals; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - pharmacology; Antibody Affinity - immunology; Body Weight - drug effects; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, SCID; Muscle Strength - drug effects; Muscle, Skeletal - drug effects; Muscle, Skeletal - pathology; Muscle, Skeletal - physiopathology; Myofibrils - drug effects; Myostatin - immunology; Neoplasms - complications; Neoplasms - drug therapy; Neoplasms, Experimental - complications; Neoplasms, Experimental - drug therapy; Transplantation, Heterologous; Treatment Outcome; Wasting Syndrome - drug therapy; Wasting Syndrome - etiology

Skeletal muscle wasting occurs in a great majority of cancer patients with advanced disease and is associated with a poor prognosis and decreased survival. Myostatin functions as a negative regulator of skeletal muscle mass and has recently become a therapeutic target for reducing the loss of skelet...